Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-LNCAb103
- Development stage
- Preclinical
- Lead developer
- Yantai Lannacheng Biotechnology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-LNCAb103 is a preclinical therapeutic radiopharmaceutical being developed by LNC Pharma for the treatment of Gastrin-releasing peptide receptor (GRPR)-positive tumors, including breast and prostate cancers. The agent is an antibody-based radioconjugate consisting of a monoclonal antibody (LNCAb103) that specifically targets GRPR, labeled with the beta-emitting radioisotope Lutetium-177 (177Lu). GRPR is a G protein-coupled receptor that is highly expressed in several solid tumors, where it plays a role in tumor cell proliferation and survival. By binding to these receptors on the surface of cancer cells, 177Lu-LNCAb103 delivers targeted cytotoxic ionizing radiation directly to the tumor site, inducing DNA double-strand breaks and subsequent apoptosis. This targeted approach is designed to maximize therapeutic efficacy while minimizing radiation exposure to healthy non-target tissues.
- Other names
- 177Lu-labeled anti-GRPR antibody
02
Targets
GRPR (Gastrin-releasing peptide receptor)
Beyond the preview
Go deeper on 177Lu-LNCAb103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-LNCAb103.